Watch ANIK. Know when insiders buy.
One email the day a filing lands. Free.
ANIK
Anika Therapeutics, Inc.
20.81
−0.19 −0.90%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
28
FLAG · shorts 28
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $278.5MP/E —DIV YIELD —FCF YIELD 0.20%REV TTM $120.7M +5.3%NET INCOME −$3.8MNET CASH $30M52W 8.40 – 22.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $32.6M | +15.6% | 65.1% | $3M | $3.3M | — | 0.24 | −$684K | $1.4M | −$2.1M | Jul 29 |
| Q1 2026 · Mar 31 | $29.6M | +13.2% | 64.2% | −$5.5M | −$5.1M | — | -0.37 | −$4.8M | $1.4M | −$6.3M | Jul 29 |
| Q4 2025 · Dec 31derived | $30.6M | +0.0% | 62.6% | $646K | $292K | — | 0.02 | $4.6M | $648K | $4M | Mar 3 |
| Q3 2025 · Sep 30 | $27.8M | −5.9% | 56.0% | −$3.2M | −$2.3M | — | -0.16 | $6.9M | $1.9M | $5M | Nov 5 |
| Q2 2025 · Jun 30 | $28.2M | −8.2% | 50.9% | −$4.2M | −$4M | — | -0.28 | −$189K | $1.5M | −$1.7M | Jul 29 |
| Q1 2025 · Mar 31 | $26.2M | −9.8% | 56.1% | −$4.3M | −$4.9M | — | -0.34 | −$130K | $2.8M | −$3M | Jul 29 |
| Q4 2024 · Dec 31derived | $30.6M | — | 56.0% | −$705K | −$21.9M | — | -1.49 | $1.6M | $1.3M | $275K | Mar 3 |
| Q3 2024 · Sep 30 | $29.6M | −28.7% | 65.7% | −$81K | −$29.9M | — | -2.03 | $5M | $1.2M | $3.8M | Nov 5 |
| Q2 2024 · Jun 30 | $30.7M | — | 66.7% | −$1.8M | −$88K | — | 0.00 | −$1.1M | $3.4M | −$4.5M | Nov 5 |
| Q1 2024 · Mar 31 | $29M | — | 65.4% | −$2.5M | −$4.5M | — | -0.31 | −$126K | $1.8M | −$1.9M | Nov 5 |
| Q4 2023 · Dec 31derived | −$2.9M | — | -199.1% | $24.7M | −$63M | — | -4.30 | $3.6M | $1.8M | $1.8M | Mar 3 |
| Q3 2023 · Sep 30 | $41.5M | — | 60.2% | −$7.7M | −$6.6M | — | -0.45 | $6.5M | $741K | $5.7M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $112.8M | 56.6% | −$11.1M | −$10.9M | -9.6% | -0.76 | $11.2M | $6.8M | $4.4M | $9.5M | — |
| FY2024 · to Dec 31 | $119.9M | 63.4% | −$5.1M | −$56.4M | -47.0% | -3.83 | $5.4M | $7.7M | −$2.3M | $10.9M | — |
| FY2023 · to Dec 31 | $120.8M | 68.3% | $844K | −$82.7M | -68.4% | -5.64 | −$1.8M | $5.4M | −$7.2M | $5M | — |
| FY2022 · to Dec 31 | $113.8M | 64.3% | $3.7M | −$14.9M | -13.1% | -1.02 | $4.4M | $7.5M | −$3.1M | $0 | — |
| FY2021 · to Dec 31 | $147.8M | 56.1% | $2.6M | $4.1M | 2.8% | 0.28 | $8.4M | $5.1M | $3.3M | $0 | — |
| FY2020 · to Dec 31 | $130.5M | 52.9% | −$28.3M | −$24M | -18.4% | -1.69 | $13.1M | $1.6M | $11.4M | $0 | — |
Every number comes from Anika Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.